DOSE — Rapid Dose Therapeutics Balance Sheet
0.000.00%
- CA$23.92m
- CA$29.23m
- CA$2.09m
- 15
- 11
- 53
- 15
Annual balance sheet for Rapid Dose Therapeutics, fiscal year end - February 28th, CAD millions except per share, conversion factor applied.
2021 February 28th | 2022 February 28th | 2023 February 28th | 2024 February 29th | 2025 February 28th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.07 | 0.034 | 0.028 | 0.161 | 0.021 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.255 | 0.183 | 0.146 | 0.219 | 0.303 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.798 | 0.614 | 0.42 | 0.679 | 0.664 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.03 | 2.45 | 1.83 | 1.21 | 0.971 |
Total Assets | 3.83 | 3.07 | 2.25 | 1.89 | 1.63 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.74 | 2.45 | 4.7 | 2.92 | 6.84 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 5.41 | 2.82 | 4.92 | 5.04 | 6.84 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -1.58 | 0.252 | -2.67 | -3.16 | -5.21 |
Total Liabilities & Shareholders' Equity | 3.83 | 3.07 | 2.25 | 1.89 | 1.63 |
Total Common Shares Outstanding |